Clinical trial · Observational
Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein in Breast Cancer
Detection of Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein as Serum Biomarker for Breast Cancer
NCT07130162CI-TRIAL-00093812not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study aims to evaluate the serum level of PIGU protein in patients with breast cancer and its relation with clinical, laboratory and pathological data of the patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- breast cancer patients
- description
- 48 case
- interventionNames
- Diagnostic Test: Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
- label
- healthy controls
- description
- 48 case
- interventionNames
- Diagnostic Test: Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Primary outcomes (1)
- measure
- Detection of the serum level of PIGU protein in patients with breast cancer
- timeFrame
- baseline
- description
- Evaluate the relation between serum level of PIGU protein in breast cancer patients and other clinical, laboratory and pathological data of the patients.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * The study will be carried on female patients who diagnosed as breast cancer based on pathological and radiological confirmation, recruited from Clinical Oncology Departments and outpatient clinics, SECI, Assiut University Exclusion Criteria: * Patients diagnosed with other concomitant cancer. * Patients who have already received chemotherapy or radiotherapy.
References
Publications (5)
- BACKGROUNDAn S, Liu F, Shi Y. Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer. Clin Chim Acta. 2025 Mar 1;569:120183. doi: 10.1016/j.cca.2025.120183. Epub 2025 Feb 6. PMID 39922250
- BACKGROUNDGiaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1. PMID 39352042
- BACKGROUNDAzim HA, Elghazawy H, Ghazy RM, Abdelaziz AH, Abdelsalam M, Elzorkany A, Kassem L. Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2023 Mar;9:e2200387. doi: 10.1200/GO.22.00387. PMID 36888929
- BACKGROUNDThakur N, Singh R, Sunigdha, Devgan R, Sharma A. Clinicopathological prognostic factors for survival in patients with breast cancer: a retrospective study from a tertiary cancer centre from North-West India. Ecancermedicalscience. 2025 Mar 6;19:1865. doi: 10.3332/ecancer.2025.1865. eCollection 2025. PMID 40492224
- BACKGROUNDWei X, Yang W, Zhang F, Cheng F, Rao J, Lu L. PIGU promotes hepatocellular carcinoma progression through activating NF-kappaB pathway and increasing immune escape. Life Sci. 2020 Nov 1;260:118476. doi: 10.1016/j.lfs.2020.118476. Epub 2020 Sep 21. PMID 32971102